Mendelian randomization study shows long-term prevention of cardiovascular and kidney events with GLP-1R agonist and SGLT2 inhibitor therapy in low- to moderate-risk adults, suggesting safety for...
This study demonstrates the utility of biobank-scale health data for pharmacology research and suggests that, if feasible to implement in routine practice, long-term, primary prevention with an SGLT2 inhibitor or GLP-1R agonist would safely lower the risk of major adverse cardiovascular and kidney events in low- to moderate-risk adults.
No takes yet. Share an insight, caveat, or question.
Remala et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: